FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897701511> ?p ?o ?g. }

• W2897701511 endingPage "1251" @default.
• W2897701511 startingPage "1241" @default.
• W2897701511 abstract "In Brief OBJECTIVE: To assess the efficacy and tolerability of ulipristal acetate, a selective progesterone receptor modulator, for treatment of symptomatic uterine leiomyomas. METHODS: This phase 3, double-blind, double-dummy, placebo-controlled trial randomized premenopausal women (18–50 years) with uterine leiomyomas and abnormal uterine bleeding to once-daily 5 mg ulipristal, 10 mg ulipristal, or placebo in two 12-week treatment courses separated by a drug-free interval of two menses. Coprimary end points were rates of and time to amenorrhea during course 1. Change from baseline to end of course 1 in the Revised Activities subscale of the Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire was a secondary end point. A sample size of 400 was planned to compare separately each ulipristal dose with placebo. RESULTS: From January 2014 through November 2016, 432 women were randomized. Demographic characteristics were similar across treatment groups. In course 1, 68 of 162 (42.0% [97.5% CI 33.3–51.1]) and 86 of 157 (54.8% [97.5% CI 45.5–63.8]) patients treated with 5 mg and 10 mg ulipristal, respectively, compared with 0 of 113 (0.0% [97.5% CI 0.0–3.8]) patients treated with placebo achieved amenorrhea (P<.001 for each dose); most women who achieved amenorrhea did so within 10 days (time to amenorrhea, P<.001 for each dose). Significantly greater improvements in Uterine Fibroid Symptom and Health-Related Quality of Life Revised Activities subscale scores were reported with 5 mg and 10 mg ulipristal compared with placebo (least squares mean change from baseline: 48.3, 56.7, and 13.0, respectively; P<.001 for each dose). Both ulipristal doses were well tolerated; in course 1, hot flush occurred in 7.5%, 11.6%, and 1.7% of patients treated with 5 mg ulipristal, 10 mg ulipristal, and placebo, respectively. CONCLUSION: Treatment with 5 mg or 10 mg ulipristal was superior to placebo in achieving amenorrhea and generally well tolerated for the medical management of symptomatic uterine leiomyomas. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02147158. Ulipristal acetate, a selective progesterone receptor modulator, is superior to placebo in achieving amenorrhea and well tolerated for the medical management of symptomatic uterine leiomyomas." @default.
• W2897701511 created "2018-10-26" @default.
• W2897701511 creator A5000976813 @default.
• W2897701511 creator A5001930283 @default.
• W2897701511 creator A5006193467 @default.
• W2897701511 creator A5009915416 @default.
• W2897701511 creator A5009915730 @default.
• W2897701511 creator A5015923975 @default.
• W2897701511 creator A5039806141 @default.
• W2897701511 creator A5044493889 @default.
• W2897701511 creator A5050410677 @default.
• W2897701511 creator A5068697150 @default.
• W2897701511 creator A5091296451 @default.
• W2897701511 creator A5091341800 @default.
• W2897701511 date "2018-11-01" @default.
• W2897701511 modified "2023-10-10" @default.
• W2897701511 title "Ulipristal Acetate for Treatment of Uterine Leiomyomas" @default.
• W2897701511 cites W1853819257 @default.
• W2897701511 cites W1969018878 @default.
• W2897701511 cites W1983768667 @default.
• W2897701511 cites W19931880 @default.
• W2897701511 cites W1996100965 @default.
• W2897701511 cites W1998329793 @default.
• W2897701511 cites W2001262571 @default.
• W2897701511 cites W2024182413 @default.
• W2897701511 cites W2026392453 @default.
• W2897701511 cites W2031903809 @default.
• W2897701511 cites W2046956943 @default.
• W2897701511 cites W2060920420 @default.
• W2897701511 cites W2071333781 @default.
• W2897701511 cites W2094884080 @default.
• W2897701511 cites W2098707038 @default.
• W2897701511 cites W2106587450 @default.
• W2897701511 cites W2144737614 @default.
• W2897701511 cites W2156957181 @default.
• W2897701511 cites W2591950961 @default.
• W2897701511 cites W2756147682 @default.
• W2897701511 cites W2789792078 @default.
• W2897701511 cites W4210998728 @default.
• W2897701511 doi "https://doi.org/10.1097/aog.0000000000002942" @default.
• W2897701511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30303900" @default.
• W2897701511 hasPublicationYear "2018" @default.
• W2897701511 type Work @default.
• W2897701511 sameAs 2897701511 @default.
• W2897701511 citedByCount "31" @default.
• W2897701511 countsByYear W28977015112019 @default.
• W2897701511 countsByYear W28977015112020 @default.
• W2897701511 countsByYear W28977015112021 @default.
• W2897701511 countsByYear W28977015112022 @default.
• W2897701511 countsByYear W28977015112023 @default.
• W2897701511 crossrefType "journal-article" @default.
• W2897701511 hasAuthorship W2897701511A5000976813 @default.
• W2897701511 hasAuthorship W2897701511A5001930283 @default.
• W2897701511 hasAuthorship W2897701511A5006193467 @default.
• W2897701511 hasAuthorship W2897701511A5009915416 @default.
• W2897701511 hasAuthorship W2897701511A5009915730 @default.
• W2897701511 hasAuthorship W2897701511A5015923975 @default.
• W2897701511 hasAuthorship W2897701511A5039806141 @default.
• W2897701511 hasAuthorship W2897701511A5044493889 @default.
• W2897701511 hasAuthorship W2897701511A5050410677 @default.
• W2897701511 hasAuthorship W2897701511A5068697150 @default.
• W2897701511 hasAuthorship W2897701511A5091296451 @default.
• W2897701511 hasAuthorship W2897701511A5091341800 @default.
• W2897701511 hasConcept C126322002 @default.
• W2897701511 hasConcept C126894567 @default.
• W2897701511 hasConcept C131872663 @default.
• W2897701511 hasConcept C141071460 @default.
• W2897701511 hasConcept C142724271 @default.
• W2897701511 hasConcept C168563851 @default.
• W2897701511 hasConcept C197934379 @default.
• W2897701511 hasConcept C204787440 @default.
• W2897701511 hasConcept C27081682 @default.
• W2897701511 hasConcept C2777486506 @default.
• W2897701511 hasConcept C2777795800 @default.
• W2897701511 hasConcept C2778058571 @default.
• W2897701511 hasConcept C2778375690 @default.
• W2897701511 hasConcept C2779066055 @default.
• W2897701511 hasConcept C2779076696 @default.
• W2897701511 hasConcept C2779234561 @default.
• W2897701511 hasConcept C2780566971 @default.
• W2897701511 hasConcept C2908647359 @default.
• W2897701511 hasConcept C29456083 @default.
• W2897701511 hasConcept C2986817661 @default.
• W2897701511 hasConcept C3017725331 @default.
• W2897701511 hasConcept C54355233 @default.
• W2897701511 hasConcept C71924100 @default.
• W2897701511 hasConcept C86803240 @default.
• W2897701511 hasConcept C99454951 @default.
• W2897701511 hasConceptScore W2897701511C126322002 @default.
• W2897701511 hasConceptScore W2897701511C126894567 @default.
• W2897701511 hasConceptScore W2897701511C131872663 @default.
• W2897701511 hasConceptScore W2897701511C141071460 @default.
• W2897701511 hasConceptScore W2897701511C142724271 @default.
• W2897701511 hasConceptScore W2897701511C168563851 @default.
• W2897701511 hasConceptScore W2897701511C197934379 @default.
• W2897701511 hasConceptScore W2897701511C204787440 @default.
• W2897701511 hasConceptScore W2897701511C27081682 @default.
• W2897701511 hasConceptScore W2897701511C2777486506 @default.

• next